NDLI: Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

Content Provider	PubMed Central
Author	Lim, S-t Wong, E-h Chuah, K-l Leong, S-s Lim, W-t Tay, M-h Toh, C-k Tan, E-h
Copyright Year	2005
Abstract	We retrospectively analysed the results of patients with advanced non-small-cell lung cancer treated with gefitinib to derive clinical factors predictive of response and a favourable survival outcome. Patients were treated with gefitinib 250 mg per day and re-evaluated 4–8 weeks later with repeat CT scan and every 8 weeks thereafter to assess response and the duration of response. Pathology review by a histopathologist was conducted, in particular to confirm a recently published result of bronchioloalveolar carcinoma histology or its components as predictive of response to gefitinib. Logistic regression and Cox regression analytical methods were applied to determine factors that could predict for response and improved overall survival. A total of 110 patients were treated. The overall response rate was 32% partial responses (PRs). Only never-smoking status was predictive of response in the logistic regression analysis, adjusted OR=6.1, 95% CI=1.7, 21.5. The presence of a PR and good performance status were predictive of a favourable survival outcome from the Cox regression modelling. Responders had an adjusted HR of 3.0, 95% CI=1.5–5.8 compared to nonresponders, while patients with ECOG status 0–1 had an adjusted HR of 0.42, 95% CI=0.25–0.72, compared with patients with ECOG status 2–4. Bronchioloalveolar carcinoma or its components were distinctly absent on pathology review. In conclusions, Never-smoking status is an important clinical predictor of a favourable response to gefitinib.
Related Links	http://dx.doi.org/10.1038/sj.bjc.6602652
Ending Page	28
Page Count	6
Starting Page	23
File Format	PDF
ISSN	00070920
e-ISSN	15321827
Journal	British Journal of Cancer
Issue Number	1
Volume Number	93
Language	English
Publisher	Nature Publishing Group
Publisher Date	2005-07-11
Access Restriction	Open
Rights Holder	Nature Publishing Group
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Molecular analysis of human papillomavirus in never-smokers with non-small cell lung cancer

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

Non-small cell lung cancer with EML4-ALKtranslocation in Chinese male never-smokers is characterized with early-onset

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

Similar Documents

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Molecular analysis of human papillomavirus in never-smokers with non-small cell lung cancer

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

Non-small cell lung cancer with EML4-ALKtranslocation in Chinese male never-smokers is characterized with early-onset

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients